MDGL vs. DRNA, RCKT, ICPT, YMAB, GBIO, ALNY, BMRN, NBIX, INCY, and UTHR
Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Dicerna Pharmaceuticals (DRNA), Rocket Pharmaceuticals (RCKT), Intercept Pharmaceuticals (ICPT), Y-mAbs Therapeutics (YMAB), Generation Bio (GBIO), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
Dicerna Pharmaceuticals (NASDAQ:DRNA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Dicerna Pharmaceuticals. MarketBeat recorded 8 mentions for Madrigal Pharmaceuticals and 0 mentions for Dicerna Pharmaceuticals. Dicerna Pharmaceuticals' average media sentiment score of 0.89 beat Madrigal Pharmaceuticals' score of 0.00 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.
Dicerna Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -64.53%. Madrigal Pharmaceuticals' return on equity of -103.08% beat Dicerna Pharmaceuticals' return on equity.
78.9% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 10.2% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Dicerna Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500.
Madrigal Pharmaceuticals has a consensus price target of $345.09, indicating a potential upside of 41.23%. Given Dicerna Pharmaceuticals' higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals received 4 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 68.49% of users gave Madrigal Pharmaceuticals an outperform vote while only 62.79% of users gave Dicerna Pharmaceuticals an outperform vote.
Summary
Madrigal Pharmaceuticals beats Dicerna Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Madrigal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Madrigal Pharmaceuticals Competitors List
Related Companies and Tools
